NASDAQ:RPRX - Royalty Pharma Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $51.88
  • Forecasted Upside: 22.66 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$42.29
▲ +0.51 (1.22%)
1 month | 3 months | 12 months
Get New Royalty Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RPRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$51.88
▲ +22.66% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Royalty Pharma in the last 3 months. The average price target is $51.88, with a high forecast of $56.00 and a low forecast of $47.00. The average price target represents a 22.66% upside from the last price of $42.29.
Hold
The current consensus among 9 investment analysts is to hold stock in Royalty Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/3/2020

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2020UBS GroupUpgradeNeutral ➝ Buy$52.00 ➝ $51.00Low
i
7/14/2020Evercore ISIInitiated CoverageHoldHigh
i
7/13/2020Bank of AmericaInitiated CoverageBuy$55.00High
i
7/13/2020CitigroupInitiated CoverageNeutral$50.00High
i
7/13/2020Morgan StanleyInitiated CoverageEqual Weight$51.00High
i
7/13/2020SunTrust BanksInitiated CoverageBuy$56.00High
i
7/13/2020UBS GroupInitiated CoverageNeutral$52.00High
i
7/13/2020JPMorgan Chase & Co.Initiated CoverageNeutral$50.00High
i
7/13/2020CowenInitiated CoverageOutperform$55.00High
i
7/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$47.00High
i
(Data available from 12/3/2015 forward)
Royalty Pharma logo
Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. The company has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. Royalty Pharma plc was founded in 1996 and is based in New York, New York.
Read More

Today's Range

Now: $42.29
$41.83
$42.71

50 Day Range

MA: $40.24
$36.12
$42.79

52 Week Range

Now: $42.29
$34.80
$56.50

Volume

1,112,916 shs

Average Volume

1,617,597 shs

Market Capitalization

$16.41 billion

P/E Ratio

N/A

Dividend Yield

1.44%

Beta

N/A